nach oben

Erschienen in:

31.10.2021 | Pancreas

A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer

verfasst von: Maria P. Fergadi, Dimitrios E. Magouliotis, Christos Rountas, Marianna Vlychou, Thanos Athanasiou, Dimitris Symeonidis, Polyxeni A. Pappa, Dimitris Zacharoulis

Erschienen in: Abdominal Radiology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to evaluate the outcomes of high-intensity focused ultrasound (HIFU) on patients with advanced pancreatic cancer.

Methods

A literature search was performed in PubMed, Scopus and Cochrane databases, in accordance with the PRISMA guidelines. The Odds Ratio, Weighted Mean Difference, and 95% Confidence Interval were evaluated by means of the Random-Effects model.

Results

Nineteen articles met the inclusion criteria, incorporating 939 patients. This study reveals that patients in the HIFU group presented increased median overall survival (OS), along with higher OS at 6 and 12 months after treatment compared with the control group (p < 0.05). Furthermore, patients treated with HIFU in conjunction with chemotherapy presented reduced levels of pain (p < 0.05) compared to the traditional treatment group. In addition, HIFU contributed to significant tumor responsiveness, in terms of CA19-9 reduction (p < 0.05). Finally, HIFU was a considerably safe treatment modality with a low incidence of complications.

Conclusion

These outcomes suggest that HIFU is a feasible and safe treatment modality for patients with advanced pancreatic cancer and provides enhanced outcomes regarding survival and quality of life. Given the lack of a significant number of randomized clinical trials, this meta-analysis represents the best currently available evidence. New randomized trials assessing HIFU are necessary to further evaluate their outcomes.

Graphic abstract

Nur mit Berechtigung zugänglich

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer 2013; Available from: http://globocan.iarc.fr, accessed on 05/06/ 2019.

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2015;65:5–29. DOI: https://doi.org/10.3322/caac.21254CrossRefPubMed

Wong HH, Chu P. Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol. 2012;3:262–284. doi: https://doi.org/10.3978/j.issn.2078-6891.2012.019CrossRefPubMedPubMedCentral

Neoptolemos JP, Urrutia R, Abbruzzese J, Büchler MW, eds. Pancreatic Cancer. New York: Springer-Verlag; 2010:LVIII, 1390.

Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8–18. DOI: https://doi.org/10.1053/j.seminoncol.2014.12.002CrossRefPubMed

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. DOI: https://doi.org/10.1158/0008-5472.CAN-14-0155CrossRefPubMed

Tempany CM, Mcdannold NJ, Hynynen K, Jolesz FA. Focused ultrasound surgery in oncology: overview and principles. Radiology. 2011;259(1):39–56. doi:https://doi.org/10.1148/radiol.11100155.CrossRefPubMedPubMedCentral

Jang HJ, Lee JY, Lee DH, Kim WH, Hwang JH. Current and future clinical applications of high-intensity focused ultrasound (HIFU) for pancreatic cancer. Gut Liver. 2010;4 Suppl 1:S57–61. DOI: https://doi.org/10.5009/gnl.2010.4.S1.S57CrossRefPubMedPubMedCentral

Dababou S, Marrocchio C, Rosenberg J, Bitton R, Pauly KB, Napoli A, et al. A meta-analysis of palliative treatment of pancreatic cancer with high intensity focused ultrasound. J Ther Ultrasound. 2017 Apr 1;5:9. doi: https://doi.org/10.1186/s40349-017-0080-4.CrossRef

10.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med. 6 (2009) e1000100. doi: https://doi.org/https://doi.org/10.1136/bmj.b2700CrossRefPubMedPubMedCentral

11.

Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011 Available from www.cochrane-handbook.org

12.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25 (2010), pp. 603–605 doi: https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

13.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629– 34. doi: https://doi.org/https://doi.org/10.1136/bmj.315.7109.629CrossRefPubMedPubMedCentral

14.

Anzidei M, Marincola BC, Bezzi M, Brachetti G, Nudo F, Cortesi E, et al. Magnetic resonance-guided high-intensity focused ultrasound treatment of locally advanced pancreatic adenocarcinoma: preliminary experience for pain palliation and local tumor control. Invest Radiol. 2014 Dec;49(12):759-65. doi: https://doi.org/10.1097/RLI.0000000000000080.CrossRefPubMed

15.

Ge HY, Miao LY, Xiong LL, Yan F, Zheng CS, Wang JR, et al. High-intensity focused ultrasound treatment of late-stage pancreatic body carcinoma: optimal tumor depth for safe ablation. Ultrasound Med Biol. 2014 May;40(5):947-55. doi: https://doi.org/10.1016/j.ultrasmedbio.2013.11.020.CrossRefPubMed

16.

Guo X, Zhu H, Zhou K, Jin C, Yang Y, Zhang J, et al. Effects of high-intensity focused ultrasound treatment on peripancreatic arterial and venous blood vessels in pancreatic cancer. Oncol Lett. 2020 Jun;19(6):3839-3850. doi: https://doi.org/10.3892/ol.2020.11511.CrossRefPubMedPubMedCentral

17.

Ji Y, Zhang Y, Zhu J, Zhu L, Zhu Y, Hu K, et al. Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China. Cancer Manag Res. 2018 Oct 9;10:4439-4446. doi: https://doi.org/10.2147/CMAR.S173740.CrossRef

18.

Jung SE, Cho SH, Jang JH, Han JY. High-intensity focused ultrasound ablation in hepatic and pancreatic cancer: complications. Abdom Imaging. 2011 Apr;36(2):185-95. doi: https://doi.org/10.1007/s00261-010-9628-2.CrossRefPubMed

19.

Li YJ, Huang GL, Sun XL, Zhao XC, Li ZG. The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World J Surg Oncol. 2016 Feb 29;14:60. doi: https://doi.org/10.1186/s12957-016-0809-5.CrossRef

20.

Li X, Wang K, Zheng L, Meng Z. Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. Am J Cancer Res. 2015 Dec 15;6(1):84-90.PubMedPubMedCentral

21.

Li PZ, Zhu SH, He W, Zhu LY, Liu SP, Liu Y, et al. High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2012 Dec 15;11(6):655-60. doi: https://doi.org/10.1016/s1499-3872(12)60241-0.CrossRefPubMed

22.

Lv W, Yan T, Wang G, Zhao W, Zhang T, Zhou D. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag. 2016 May 2;12:687-91. doi: https://doi.org/10.2147/TCRM.S90567.CrossRef

23.

Marinova M, Feradova H, Gonzalez-Carmona MA, Conrad R, Tonguc T, Thudium M, et al. Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers. Eur Radiol. 2021 Jan 23. doi: https://doi.org/10.1007/s00330-020-07682-z. Epub ahead of print.

24.

Ning Z, Xie J, Chen Q, Zhang C, Xu L, Song L, et al. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther. 2019 Feb 1;12:1021-1029. doi: https://doi.org/10.2147/OTT.S185424.CrossRef

25.

Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Vigna PD, et al. High-intensity focused ultrasound ablation: effective and safe therapy for solid tumors in difficult locations. AJR Am J Roentgenol. 2010 Sep;195(3):W245-52. doi: https://doi.org/10.2214/AJR.09.3321.CrossRefPubMed

26.

Sung HY, Jung SE, Cho SH, Zhou K, Han JY, Han ST, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011 Oct;40(7):1080-6. doi: https://doi.org/10.1097/MPA.0b013e31821fde24.CrossRefPubMed

27.

Tao SF, Gu WH, Gu JC, Zhu ML, Wang Q, Zheng LZ. A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer. Onco Targets Ther. 2019 Nov 15;12:9735-9745. doi: https://doi.org/10.2147/OTT.S220299.CrossRef

28.

Thudium M, Bette B, Tonguc T, Ghaei S, Conrad R, Becher MU, et al. Multidisciplinary management and outcome in pancreatic cancer patients treated with high-intensity focused ultrasound. Int J Hyperthermia. 2020;37(1):456-462. doi: https://doi.org/10.1080/02656736.2020.1762006.CrossRefPubMed

29.

Wang K, Chen Z, Meng Z, Lin J, Zhou Z, Wang P, et al. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int J Hyperthermia. 2011;27(2):101-7. doi: https://doi.org/10.3109/02656736.2010.525588.CrossRefPubMed

30.

Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, et al. Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology. 2005 Sep;236(3):1034-40. doi: https://doi.org/10.1148/radiol.2362041105.CrossRefPubMed

31.

Zhao J, Zhao F, Shi Y, Deng Y, Hu X, Shen H. The efficacy of high-intensity focused ultrasound (HIFU) in advanced pancreatic cancer. Chin. J. Clin. Oncol. 5, 183–186 (2008). https://doi.org/https://doi.org/10.1007/s11805-008-0183-3CrossRef

32.

Zhao H, Yang G, Wang D, Yu X, Zhang Y, Zhu J, et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs. 2010 Apr;21(4):447-52. doi: https://doi.org/10.1097/CAD.0b013e32833641a7.CrossRefPubMed

33.

Sehgal S, Ghaleb A. Neurolytic celiac plexus block for pancreatic cancer pain: a review of literature. Indian J Pain. 2013;27(3):121. DOI: https://doi.org/10.4103/0970-5333.124584CrossRef

34.

Zhou Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer. Gastroenterol Res Pract. 2014;2014:205325. doi:https://doi.org/10.1155/2014/205325.CrossRefPubMedPubMedCentral

35.

Dimitrov D, Andreev T, Feradova H, Ignatov B, Zhou K, Johnson C, et al. Multimodality treatment by FOLFOX plus HIFU in a case of advanced pancreatic carcinoma. A case report. JOP. 2015;16(1):66–9. doi: https://doi.org/10.6092/1590-8577/2900.CrossRefPubMed

36.

Zhu X, Meng Z, Chen Z, Wang K, Yu B, Zhan H, et al. Metastatic adenocarcinoma of the epididymis from pancreatic cancer successfully treated by chemotherapy and high-intensity focused ultrasound therapy: a case report and review of the literature. Pancreas. 2011;40(7):116O–2. DOI: https://doi.org/10.1097/MPA.0b013e318221816dCrossRef

37.

Ischia S, et al. Three posterior percutaneous celiac plexus block techniques. A prospective, randomized study in 61 patients with pancreatic cancer pain. Anesthesiology. 1992;76(4):534–40.

Titel: A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer
verfasst von: Maria P. Fergadi
Dimitrios E. Magouliotis
Christos Rountas
Marianna Vlychou
Thanos Athanasiou
Dimitris Symeonidis
Polyxeni A. Pappa
Dimitris Zacharoulis
Publikationsdatum: 31.10.2021
Verlag: Springer US
Erschienen in: Abdominal Radiology / Ausgabe 1/2022
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-021-03334-y

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer